Literature DB >> 18793788

The effect of early versus delayed challenge after vaccination in controlling SHIV 89.6P infection.

Leslie L Chavez1, Miles P Davenport, John W Shiver, Lynda G Tussey, Kara S Cox, Margaret Bachinsky, Fubao Wang, Lingyi Huang, William A Schleif, Mary-Ellen Davies, Aimin Tang, Danilo R Casimiro, Alan S Perelson, Ruy M Ribeiro.   

Abstract

We sought to determine how effectively a CD8+ T cell inducing vaccine controls SHIV-89.6P infection in rhesus macaques at a range of challenge times post-vaccination. To this end, twenty eight Mamu-A*01+ rhesus macaques were given replication incompetent human serotype 5 adenovirus vector expressing SIVmac239 gag DNA and boosted 24 weeks later. Groups of 4 monkeys were then challenged with SHIV-89.6P at 1, 3, 6, 12, and 24 weeks after the boost. We compared the kinetics of viral load, CD4+ and virus-specific CD8+ T cells in these macaques. Measurements of CD8+ T cells taken before challenge show an exponential decay between 1 and 12 weeks following vaccination (p<0.0001). After week 12, no further decay was observed. Twenty of 24 vaccinated animals maintained more CD4+ T cells and kept their viral load at least one order of magnitude lower than the control animals throughout the chronic phase of the study. All 24 vaccinated animals survived the duration of the study. The viral and T cell kinetics over the first two weeks differed between the vaccinated groups, with more recent vaccination improving the early control of virus (p-value=0.027). The rates of virus specific CD8+ T cell expansion were greater in animals having higher viral loads at one week (r=0.45, p=0.029), suggesting that the kinetics of early viral load may have a role in virus specific CD8+ T cell generation, although these early differences did not lead to different clinical outcomes within the vaccinated animals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793788      PMCID: PMC2664825          DOI: 10.1016/j.virol.2008.07.042

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  20 in total

1.  Skewed maturation of memory HIV-specific CD8 T lymphocytes.

Authors:  P Champagne; G S Ogg; A S King; C Knabenhans; K Ellefsen; M Nobile; V Appay; G P Rizzardi; S Fleury; M Lipp; R Förster; S Rowland-Jones; R P Sékaly; A J McMichael; G Pantaleo
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

2.  AIDS vaccine models: challenging challenge viruses.

Authors:  Mark B Feinberg; John P Moore
Journal:  Nat Med       Date:  2002-03       Impact factor: 53.440

Review 3.  The assessment of antigen-specific CD8+ T cells through the combination of MHC class I tetramer and intracellular staining.

Authors:  Victor Appay; Sarah L Rowland-Jones
Journal:  J Immunol Methods       Date:  2002-10-01       Impact factor: 2.303

4.  Different dynamics of CD4+ and CD8+ T cell responses during and after acute lymphocytic choriomeningitis virus infection.

Authors:  Rob J De Boer; Dirk Homann; Alan S Perelson
Journal:  J Immunol       Date:  2003-10-15       Impact factor: 5.422

5.  Kinetics of virus-specific CD8+ T cells and the control of human immunodeficiency virus infection.

Authors:  Miles P Davenport; Ruy M Ribeiro; Alan S Perelson
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

6.  Direct ex vivo analysis reveals distinct phenotypic patterns of HIV-specific CD8(+) T lymphocyte activation in response to therapeutic manipulation of virus load.

Authors:  A Oxenius; H F Günthard; B Hirschel; S Fidler; J N Weber; P J Easterbrook; J I Bell; R E Phillips; D A Price
Journal:  Eur J Immunol       Date:  2001-04       Impact factor: 5.532

7.  Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Authors:  John W Shiver; Tong-Ming Fu; Ling Chen; Danilo R Casimiro; Mary-Ellen Davies; Robert K Evans; Zhi-Qiang Zhang; Adam J Simon; Wendy L Trigona; Sheri A Dubey; Lingyi Huang; Virginia A Harris; Romnie S Long; Xiaoping Liang; Larry Handt; William A Schleif; Lan Zhu; Daniel C Freed; Natasha V Persaud; Liming Guan; Kara S Punt; Aimin Tang; Minchun Chen; Keith A Wilson; Kelly B Collins; Gwendolyn J Heidecker; V Rose Fernandez; Helen C Perry; Joseph G Joyce; Karen M Grimm; James C Cook; Paul M Keller; Denise S Kresock; Henryk Mach; Robert D Troutman; Lynne A Isopi; Donna M Williams; Zheng Xu; Kathryn E Bohannon; David B Volkin; David C Montefiori; Ayako Miura; Georgia R Krivulka; Michelle A Lifton; Marcelo J Kuroda; Jörn E Schmitz; Norman L Letvin; Michael J Caulfield; Andrew J Bett; Rima Youil; David C Kaslow; Emilio A Emini
Journal:  Nature       Date:  2002-01-17       Impact factor: 49.962

8.  Expansion and exhaustion of T-cell responses during mutational escape from long-term viral control in two DNA/modified vaccinia virus Ankara-vaccinated and simian-human immunodeficiency virus SHIV-89.6P-challenged macaques.

Authors:  Shanmugalakshmi Sadagopal; Rama Rao Amara; Sunil Kannanganat; Sunita Sharma; Lakshmi Chennareddi; Harriet L Robinson
Journal:  J Virol       Date:  2008-01-30       Impact factor: 5.103

9.  Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability.

Authors:  Barbara Ridolfi; Domenico Genovese; Claudio Argentini; Maria Teresa Maggiorella; Leonardo Sernicola; Stefano Buttò; Fausto Titti; Alessandra Borsetti; Barbara Ensoli
Journal:  Virus Genes       Date:  2007-11-30       Impact factor: 2.332

10.  Viral outcome of simian-human immunodeficiency virus SHIV-89.6P adapted to cynomolgus monkeys.

Authors:  A Borsetti; S Baroncelli; M T Maggiorella; S Bellino; S Moretti; L Sernicola; R Belli; B Ridolfi; S Farcomeni; D R M Negri; A Cafaro; B Ensoli; F Titti
Journal:  Arch Virol       Date:  2007-12-15       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.